PMID: 12757969May 22, 2003Paper

Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients

Drug and Alcohol Dependence
Thomas KostenKishor Gonsai

Abstract

Co-dependence on opiates and cocaine occurs in about 60% of patients entering methadone treatment and has a poor prognosis. However, we recently found that desipramine (DMI) could be combined with buprenorphine to significantly reduce combined opiate and cocaine use among these dually dependent patients. Furthermore, contingency management (CM) has been quite potent in reducing cocaine abuse during methadone maintenance. To test the efficacy of combining CM with these medications we designed a 12-week, randomized, double blind, four cell trial evaluating DMI (150 mg/day) or placebo plus CM or a non-contingent voucher control in 160 cocaine abusers maintained on buprenorphine (median 16 mg daily). Cocaine-free and combined opiate and cocaine-free urines increased more rapidly over time in those treated with either DMI or CM, and those receiving both interventions had more drug-free urines (50%) than the other three treatment groups (25-29%). Self reported opiate and cocaine use and depressive and opioid withdrawal symptoms showed no differences among the groups and symptom levels did not correlate with urine toxicology results. Lower DMI plasma levels (average 125 ng/ml) were associated with greater cocaine-free urines. DMI and ...Continue Reading

References

Jul 1, 1978·The International Journal of the Addictions·M Stitzer, G Bigelow
Jun 11, 1991·The American Journal of Drug and Alcohol Abuse·W W WeddingtonJ H Jaffe
Oct 1, 1989·Biological Psychiatry·T R KostenC Morgan
Jan 1, 1988·Addictive Behaviors·S MaguraD S Lipton
Apr 1, 1995·The Journal of Nervous and Mental Disease·K M CarrollB J Rounsaville
Jun 1, 1993·The Journal of Nervous and Mental Disease·T R KostenJ Falcioni
Jun 3, 1998·Experimental and Clinical Psychopharmacology·J M SchmitzJ Grabowski
Nov 6, 1998·Journal of Consulting and Clinical Psychology·K SilvermanK L Preston
Feb 11, 2000·Drug and Alcohol Dependence·J D GriffithD D Simpson
Mar 9, 2000·Drug and Alcohol Dependence·J L Sorensen, A L Copeland
Apr 26, 2000·Journal of Consulting and Clinical Psychology·N M PetryH R Kranzler
Aug 25, 2001·Experimental and Clinical Psychopharmacology·K SilvermanG E Bigelow
Oct 11, 2001·Journal of Clinical Psychopharmacology·J GrabowskiF G Moeller
Feb 1, 1960·Journal of Neurology, Neurosurgery, and Psychiatry·M HAMILTON

❮ Previous
Next ❯

Citations

Apr 24, 2007·Neurotoxicity Research·Neil E Paterson, Athina Markou
Feb 8, 2006·AIDS and Behavior·Steffanie A Strathdee, Thomas L Patterson
Oct 12, 2005·Current Psychiatry Reports·Kathleen M Carroll
Aug 11, 2010·Current Psychiatry Reports·Kyle M Kampman
Jul 9, 2005·Drug and Alcohol Dependence·Alison OlivetoThomas R Kosten
May 26, 2005·Drug and Alcohol Dependence·David McDowellEva Petkova
Jun 16, 2010·Experimental and Clinical Psychopharmacology·Joy M SchmitzF Gerard Moeller
Jun 29, 2011·Experimental and Clinical Psychopharmacology·Nancy M Petry, John M Roll
Feb 24, 2012·Journal of Addictive Diseases·Ayman FareedKaren Drexler
Sep 12, 2009·Journal of Clinical Psychopharmacology·Janette McGaughAlison Oliveto
Aug 25, 2007·Annual Review of Clinical Psychology·Maxine Stitzer, Nancy Petry
Mar 7, 2014·Psychopharmacology·Natalie E ZlebnikMarilyn E Carroll
Jul 7, 2007·The American Journal of Drug and Alcohol Abuse·Kathleen M Carroll, Bruce J Rounsaville
Jul 7, 2007·The American Journal of Drug and Alcohol Abuse·F Gerard MoellerJohn Grabowski
Aug 10, 2011·The American Journal of Drug and Alcohol Abuse·Carolyn J Plater-ZyberkAndrew Worster
May 30, 2012·The Psychiatric Clinics of North America·John J Mariani, Frances R Levin
Aug 18, 2009·Pharmacology & Therapeutics·Noushin Yahyavi-Firouz-Abadi, Ronald E See
Feb 29, 2008·Clinical Pharmacology and Therapeutics·M L Stitzer, R Vandrey
Sep 11, 2014·Annals of the New York Academy of Sciences·Kathleen M Carroll
Nov 24, 2004·Biological Psychiatry·Edward V NunesFrances R Levin
Oct 24, 2006·Journal of Affective Disorders·Einat PelesMiriam Adelson
Feb 1, 2006·Addiction·Jennifer Plebani LussierStephen T Higgins
Oct 22, 2013·Neuroscience and Biobehavioral Reviews·Anna B KonovaRita Z Goldstein
Dec 20, 2011·The American Journal of Drug and Alcohol Abuse·Ayman FareedKaren Drexler
Feb 24, 2015·Substance Abuse : Official Publication of the Association for Medical Education and Research in Substance Abuse·Jeffrey D BaxterElizabeth O'Connell
Feb 23, 2011·Neuron·Marc N PotenzaBruce J Rounsaville
Feb 12, 2011·Drug and Alcohol Dependence·Frances R LevinEdward V Nunes
May 13, 2014·Drug and Alcohol Dependence·Annie UmbrichtGeorge E Bigelow
May 26, 2016·Current Psychiatry Reports·Elias Dakwar, Edward V Nunes
Jul 7, 2007·The American Journal of Drug and Alcohol Abuse·Thomas R Kosten
May 26, 2012·Journal of Psychopharmacology·A R Lingford-HughesUNKNOWN British Association for Psychopharmacology, Expert Reviewers Group
Jul 28, 2004·Drug and Alcohol Dependence·Kathleen M CarrollBruce J Rounsaville
Jul 5, 2017·The American Journal on Addictions·Ahmed N HassanTony P George
Sep 9, 2010·The Cochrane Database of Systematic Reviews·Pier Paolo PaniMarina Davoli

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.